Zoetis (ZTS) Downgraded by Hilliard Lyons

Hilliard Lyons lowered shares of Zoetis (NYSE:ZTS) to a neutral rating in a research report report published on Thursday morning, The Fly reports. The analysts noted that the move was a valuation call.

Several other research firms also recently weighed in on ZTS. Citigroup reissued a buy rating and set a $98.00 target price (up previously from $85.00) on shares of Zoetis in a research report on Thursday. Morgan Stanley downgraded Zoetis from an overweight rating to an equal weight rating and set a $70.00 target price on the stock. in a research report on Monday, March 19th. They noted that the move was a valuation call. Jefferies Group reissued a buy rating and set a $96.00 target price on shares of Zoetis in a research report on Friday, April 13th. Credit Suisse Group boosted their target price on Zoetis from $83.00 to $89.00 and gave the company an outperform rating in a research report on Thursday, April 5th. Finally, ValuEngine raised Zoetis from a hold rating to a buy rating in a research report on Monday, April 2nd. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and thirteen have given a buy rating to the stock. Zoetis currently has an average rating of Buy and a consensus target price of $81.61.

How to Become a New Pot Stock Millionaire

NYSE ZTS opened at $85.45 on Thursday. The company has a market cap of $41,445.52, a PE ratio of 35.60, a P/E/G ratio of 1.89 and a beta of 0.96. The company has a debt-to-equity ratio of 2.77, a quick ratio of 2.55 and a current ratio of 3.85. Zoetis has a fifty-two week low of $54.00 and a fifty-two week high of $86.38.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, February 15th. The company reported $0.69 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.66 by $0.03. The firm had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.40 billion. Zoetis had a return on equity of 65.96% and a net margin of 16.28%. The company’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.47 EPS. equities analysts expect that Zoetis will post 3.04 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, June 1st. Shareholders of record on Friday, April 20th will be issued a $0.126 dividend. This represents a $0.50 annualized dividend and a dividend yield of 0.59%. The ex-dividend date is Thursday, April 19th. Zoetis’s dividend payout ratio is 20.83%.

In other Zoetis news, insider Heidi C. Chen sold 37,453 shares of the company’s stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $81.02, for a total value of $3,034,442.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Heidi C. Chen sold 7,383 shares of the company’s stock in a transaction on Friday, March 16th. The stock was sold at an average price of $84.71, for a total value of $625,413.93. Following the completion of the sale, the insider now owns 20,162 shares of the company’s stock, valued at $1,707,923.02. The disclosure for this sale can be found here. Insiders sold a total of 112,952 shares of company stock valued at $9,219,843 over the last quarter. Company insiders own 0.35% of the company’s stock.

Several hedge funds have recently modified their holdings of ZTS. Harel Insurance Investments & Financial Services Ltd. purchased a new stake in shares of Zoetis in the 4th quarter worth $108,000. Steward Partners Investment Advisory LLC purchased a new stake in shares of Zoetis in the 3rd quarter worth $114,000. We Are One Seven LLC purchased a new stake in shares of Zoetis in the 4th quarter worth $120,000. Premia Global Advisors LLC purchased a new stake in shares of Zoetis in the 4th quarter worth $122,000. Finally, Icon Wealth Partners LLC purchased a new stake in shares of Zoetis in the 4th quarter worth $127,000. Institutional investors and hedge funds own 92.33% of the company’s stock.

WARNING: “Zoetis (ZTS) Downgraded by Hilliard Lyons” was posted by Week Herald and is owned by of Week Herald. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://weekherald.com/2018/04/22/zoetis-zts-downgraded-by-hilliard-lyons.html.

About Zoetis

Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

The Fly

Analyst Recommendations for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply